Basis: Four-quarter operating EBITDA / current FMP quote-based enterprise value × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The EBITDA yield is N/A as of 2026-10-06T16:03:35.305Z.
Calculation as of: 2026-10-06T16:03:35.305Z.
Quote observation: 2026-10-06T16:00:26.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: f23401f377ae0c42cb4058dfce1620411e9c781823cb8ffdb9eedba1333334c1
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EBITDA YIELD
N/A
Market Cap
$5.98B
EBITDA Yield
2.21%
TTM Avg
1.62%
3Y Avg
2.24%
5Y Avg
4.65%
Market Cap
$5.80B
EBITDA Yield
1.81%
TTM Avg
1.65%
3Y Avg
1.60%
5Y Avg
1.99%
Market Cap
$5.56B
EBITDA Yield
3.24%
TTM Avg
3.04%
3Y Avg
3.04%
5Y Avg
3.04%
Market Cap
$5.38B
EBITDA Yield
3.42%
TTM Avg
10.75%
3Y Avg
10.29%
5Y Avg
10.29%
Market Cap
$6.51B
EBITDA Yield
5.88%
TTM Avg
7.53%
3Y Avg
7.75%
5Y Avg
5.52%
| NAME | MARKET CAP | EBITDA YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Iovance Biotherapeutics, Inc. (IOVA) | $5.93B | N/A | N/A | N/A | N/A |
| Ligand Pharmaceuticals Incorporated (LGND)vs › | $5.98B | 2.21% | 1.62% | 2.24% | 4.65% |
| GRAIL Inc. (GRAL)vs › | $5.98B | N/A | N/A | N/A | N/A |
| Kiniksa Pharmaceuticals International, plc (KNSA)vs › | $5.80B | 1.81% | 1.65% | 1.60% | 1.99% |
| CG Oncology Inc. (CGON)vs › | $5.77B | N/A | N/A | N/A | N/A |
| RadNet, Inc. (RDNT)vs › | $5.54B | 4.60% | 4.21% | 4.87% | 6.47% |
| MiniMed Group, Inc. Common Stock (MMED)vs › | $5.56B | 3.24% | 3.04% | 3.04% | 3.04% |
| PTC Therapeutics, Inc. (PTCT)vs › | $5.38B | 3.42% | 10.75% | 10.29% | 10.29% |
| Lantheus Holdings, Inc. (LNTH)vs › | $6.51B | 5.88% | 7.53% | 7.75% | 5.52% |
| Doximity, Inc. (DOCS)vs › | $5.36B | 4.16% | 4.42% | 3.12% | 2.52% |
EBITDA Yield = TTM EBITDA / Enterprise Value
EBITDA yield is the inverse of EV/EBITDA, expressing trailing pre-interest, pre-tax operating cash generation as a percentage of enterprise value. Comparable across leverage levels; higher is cheaper. Not meaningful for banks and insurers.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
